Skip to main content
    R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $43.73
    -0.73 (-1.64%)

    Market Cap: $837.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rigel Pharmaceuticals Inc (RIGL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Rigel Pharmaceuticals are Oric Pharmaceuticals (ORIC), Pharming Group NV (PHAR) and Silence Therapeutics (SLN). By market cap, Rigel Pharmaceuticals ranks 7th of the 13 companies on this page; Nurix Therapeutics (NRIX) is the largest at $1.69B.

    Peer Comparison

    RIGL's revenue growth of 16.5% is above the peer median of 4.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Rigel Pharmaceuticals (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    Silence Therapeutics PLC (SLN)$1.23BN/A882.5x0.0%N/A197.2%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Sagimet Biosciences Inc. Series A Common Stock (SGMT)$735.18MN/AN/A0.0%N/A0.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Sellas Life Sciences Group Inc (SLS)$1.60BN/AN/A0.0%N/A-82.5%0.00%
    Monte Rosa Therapeutics Inc (GLUE)$800.67MN/A13.3x-186.2%N/A325.8%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Peer median$853.26M22.9x3.8x0.0%-3.5%4.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Rigel Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Pharming Group NV (PHAR)
    Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States...
    PHAR competitors
    Silence Therapeutics PLC (SLN)
    Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology...
    SLN competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors
    Sagimet Biosciences Inc. Series A Common Stock (SGMT)
    Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases...
    SGMT competitors
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Sellas Life Sciences Group Inc (SLS)
    SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications...
    SLS competitors
    Monte Rosa Therapeutics Inc (GLUE)
    Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural...
    GLUE competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors

    Frequently Asked Questions About RIGL

    Who are Rigel Pharmaceuticals' main competitors?

    The companies most similar to Rigel Pharmaceuticals include Oric Pharmaceuticals (ORIC), Pharming Group NV (PHAR), Silence Therapeutics (SLN), Immix Biopharma (IMMX) and Prime Medicine, Inc. Common Stock (PRME), listed from the closest match.

    Who is Rigel Pharmaceuticals' biggest competitor?

    Nurix Therapeutics (NRIX) is the largest of the similar companies at $1.69B; Oric Pharmaceuticals (ORIC) is the closest match by business profile, size, sector and industry.

    How does RIGL stock compare with its competitors?

    RIGL's P/E is 14.2x against a peer median of 22.9x; its P/S is 2.8x against a peer median of 3.8x; its net margin is 106.6% against a peer median of 0.0%.

    Which of Rigel Pharmaceuticals' competitors pays a higher dividend?

    Rigel Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Rigel Pharmaceuticals bigger than its competitors?

    No. Rigel Pharmaceuticals is 7th by market cap among the 13 companies on this page; the largest is Nurix Therapeutics (NRIX) at $1.69B.